{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=6",
    "query": {
      "intervention": "Lynparza",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 226,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T08:16:11.007Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02769962",
      "title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Urothelial Cancer",
        "Lung Neoplasms",
        "Small Cell Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EP0057",
          "type": "DRUG"
        },
        {
          "name": "olaparib",
          "type": "DRUG"
        },
        {
          "name": "CT scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT chest, abdomen, and pelvis",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2016-05-09",
      "completion_date": "2025-03-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02769962"
    },
    {
      "nct_id": "NCT02264678",
      "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Administration of ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with olaparib",
          "type": "DRUG"
        },
        {
          "name": "Administation of ceralasertib in combination with durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib and olaparib",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib and durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with AZD5305",
          "type": "DRUG"
        },
        {
          "name": "Administration of ceralasertib in combination with carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 358,
      "start_date": "2014-10-31",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02264678"
    },
    {
      "nct_id": "NCT05252390",
      "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Cancer of Ovary",
        "Cancer of the Ovary",
        "Ovary Neoplasm",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Pancreas Neoplasm",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration Resistant Prostatic Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Triple-negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Breast Tumor"
      ],
      "interventions": [
        {
          "name": "NUV-868",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2022-03-29",
      "completion_date": "2024-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05252390"
    },
    {
      "nct_id": "NCT03923270",
      "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer Extensive Stage",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill",
          "type": "DRUG"
        },
        {
          "name": "Thoracic Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-06-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923270"
    },
    {
      "nct_id": "NCT03976362",
      "title": "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell, Non-small-cell Lung"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 851,
      "start_date": "2019-06-28",
      "completion_date": "2026-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Burbank, California • Boca Raton, Florida + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03976362"
    },
    {
      "nct_id": "NCT03212274",
      "title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Glioblastoma",
        "Recurrent Cholangiocarcinoma",
        "Recurrent Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "WHO Grade 2 Glioma",
        "WHO Grade 3 Glioma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-01-30",
      "completion_date": "2027-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 51,
      "location_summary": "Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03212274"
    },
    {
      "nct_id": "NCT03025035",
      "title": "Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yuan Yuan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-09-10",
      "completion_date": "2025-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03025035"
    },
    {
      "nct_id": "NCT03531840",
      "title": "Olaparib in People With Malignant Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "ClinOmics",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 23,
      "start_date": "2018-07-11",
      "completion_date": "2020-10-21",
      "has_results": true,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531840"
    },
    {
      "nct_id": "NCT03532880",
      "title": "A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Olaparib Pill 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Olaparib Pill 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2018-07-12",
      "completion_date": "2025-02-04",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 9,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03532880"
    },
    {
      "nct_id": "NCT03012321",
      "title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic Castration-Resistant",
        "Abnormal DNA Repair",
        "Metastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2017-01-12",
      "completion_date": "2027-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-16T08:16:11.007Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012321"
    }
  ]
}